Baike Biotech (688276.SH) issued an announcement. The company recently received from the Drug Evaluation Center of the State Drug Administration...
Zhitong Finance App News, Baike Biotech (688276.SH) issued an announcement. The company recently received the “Notice of Acceptance” issued by the Drug Evaluation Center of the State Drug Administration for the marketing license application for a live attenuated nasal spray influenza vaccine. If this vaccine variety is successfully approved for marketing, it will facilitate the promotion and use of the company's influenza vaccine, optimize the company's product structure, further enhance the company's core competitiveness, and lay a solid foundation for the company's continued steady development.
The live attenuated nasal spray vaccine accepted by the company this time can form the first immune barrier to prevent influenza virus invasion in the respiratory tract by simulating a natural infection with the influenza virus through nasal inoculation. The dosage form of the vaccine was improved on the basis of the company's freeze-dried live attenuated nasal spray influenza vaccine product. The original freeze-dried dosage form was upgraded to a liquid dosage form, making vaccination more convenient, and the applicable population was extended to people aged 3 to 59.